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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S400then irradiated with gamma-ray for preventing a replication of the cell
and went to a cell death.
Methods: MR images acquired at baseline (pre-treatment), as well as
6 and 12 months post-treatment, were evaluated by two experi-
enced musculoskeletal radiologists in a blinded fashion using a
modiﬁed WORMS (Whole Organ Magnetic Resonance Imaging Score)
method. After this scoring, the images were presented to the two
radiologists again, in time sequence, and radiological impressions
were generated for cartilage, and any signiﬁcant visible trends or
changes were identiﬁed. During the un-blinded radiological evalua-
tion a set of patients was noted to have improvements in the
cartilage.
Results: The following improvements were observed: full thickness
cartilage defect ﬁlling, generalized cartilage thickening in the defect
area, and improvement or resolution of cartilage blisters. One patient
showed several of these ﬁndings, and additionally showed considerable
bone regeneration (bone remodeling) and cartilage regeneration in the
trochlea, restoring the trochlea shape. Although these patients dem-
onstrated many areas of improvement, in some patients there was
evidence of progression of OA as well.
Conclusions: Based on these ﬁndings, there was an indication that in
certain cases this treatment induced cartilage regeneration.
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ASPIRIN IS ASSOCIATED WITH REDUCED CARTILAGE LOSS IN KNEE
OSTEOARTHRITIS: DATA FROM A COHORT STUDY
A. Wluka y, C. Ding z, Y. Wang y, G. Jones z, F. Cicuttini y. yMonash Univ.,
Melbourne, Australia; zMenzies Res. Inst. Tasmania, Hobart, Australia
Purpose: Inﬂammation and vascular disease are important in the
pathogenesis of osteoarthritis. Low dose aspirin has anti-inﬂammatory
and vasculoprotective effects. This study examined whether use of low
dose aspirin affects change in knee cartilage volume in osteoarthritis.
Methods: Participants from the Melbourne osteoarthritis cohort were
classiﬁed as users and non users of aspirin based aspirin use (<300 mg/
day) at baseline. Participant’s knees were imaged twice over 2 years.
Medial and lateral tibial cartilage volumes were measured and change
in cartilage volume was calculated.
Results: Twenty one (18%) of participants were aspirin users at baseline.
After adjustment for age, gender, body mass index and severity of
radiographic change, annual change in medial tibial cartilage volume
was43mm3 (95% conﬁdence intervals (CI)94, 5) in aspirin users and
101 mm3 (95% CI 124, 77) in non-users (P ¼ 0.048 for difference).
Similar results were seen for annual percentage loss (1.9% vs. 5.4%, p ¼
0.03). No difference was observed for lateral tibial cartilage change (p ¼
0.88)
Conclusions: Low dose aspirin use was associated with reduced medial
tibial cartilage loss over 2 years in people with knee osteoarthritis. This
data should be considered hypothesis generating and clinical trials are
required to conﬁrm efﬁcacy.
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DYSLIPIDEMIA IN PATIENTS WITH OSTEOARTHRITIS AND TYPE 2
DIABETES MELLITUS
M. Oliinyk. Kharkov Natl. Med. Univ., Kharkov, Ukraine
Purpose: To investigate inﬂuence of dyslipidemia to articular syndrome
and glycosylated hemoglobin (HbA1c) in patients with osteoarthritis
(OA) and type 2 diabetes mellitus (T2DM).
Methods:We examined 60 patients with knee OA and T2DM (28males,
age 58.7  4.7 years). Baseline characteristics of patients included his-
tory of OA (6.2  2.1 years), T2DM (7.3  2.7 years). All patients were
divided into 2 groups: 1st group – patients with OA, T2DM and con-
comitant dyslipidemia (n ¼ 31), 2nd group (n ¼ 29) – patients with OA,
T2DM and without concomitant dyslipidemia. The levels of total cho-
lesterol (TC), low-density lipoprotein cholesterol (LDL), very LDL (VLDL),
triglycerides (TG), high-density lipoprotein cholesterol (HDL), of HbA1c,
C-reactive protein were determined. All patients were made X-ray
examination of knees.
Results: Among the 1st group of patients the level of HbA1c was
signiﬁcantly correlated with TC level (r ¼ 0.58; p < 0.05), LDL (r ¼
0.48; p < 0.05), TG (r ¼ 0.42; p < 0.05), HDL (r ¼ 0.46; p < 0.05).
The study found that the level of C-reactive protein was sig-
niﬁcantly higher in patients with concomitant dyslipidemia (p <0.05). The degree of radiographic changes was signiﬁcantly more
increased in patients in the 1st group. We also noticed the severity
of radiographic changes were signiﬁcantly correlated with duration
of T2DM (r ¼ 0.41, p < 0.05).
Conclusions: Dyslipidemia can negatively affect the severity of articular
syndrome and HbA1c in patients with OA and T2DM.We recommend to
determine the level of lipid metabolism in patients with OA and T2DM
for prescribing adequate lipid-lowering therapy that can minimize the
risk of possible complications.Pain and Disability
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ASSESSMENT OF CHRONIC PAIN AFTER TOTAL KNEE REPLACEMENT:
DEVELOPMENT OF A CORE OUTCOME SET
V. Wylde y, J. Bruce z, F. MacKichan y, R. Gooberman-Hill y. yUniv. of
Bristol, Bristol, United Kingdom; zUniv. of Warwick, Warwick, United
Kingdom
Purpose: Total knee replacement (TKR) can be a successful operation
for providing pain relief, however approximately 20% of patients con-
tinue to experience chronic pain after TKR. The Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
includes pain in its recommendations for core outcomes to assess in
clinical trials of pain treatment. However, pain is multidimensional and
there are no recommendations about which aspects of pain should be
assessed. In this project, we aim to develop a core outcome set for the
assessment of chronic pain after TKR using a Delphi survey. This core
outcome set will represent the minimum pain information that should
be measured and reported in clinical trials focusing on chronic pain
after TKR.
Methods: This project is funded through a National Institute for Health
Research Programme Development Grant on the treatment and man-
agement of chronic pain after TKR (the STAR programme).
Phase I: identiﬁcation of pain features
A Delphi survey requires that a long-list of possible domains has been
developed, which adequately reﬂects previous research and the views
of patients and clinicians. A list of pain feature that can be assessed after
TKR has been developed through three studies:
1.) Systematic review of 1,164 articles which assessed pain at a mini-
mum of 3-months after TKR.
2.) Three focus groups with 14 health care professionals.
3.) Brief interviews with 50 patients experiencing chronic pain after
TKR.
Phase II: Delphi survey
A 3-round Delphi survey with patients and clinicians is being under-
taken to achieve consensus in the reduction of the long-list of pain
features to a core outcome set. In round 1, participants are asked to rate
the importance of assessing each pain feature from 1–9 (very important
to very unimportant). Those pain features given an importance rating of
7–9 by at least 70% of each of the two panels (patients and clinicians)
and rated as 1–3 by less than 15%, or given an important rating of 7–9 by
90% or more members of one panel, are retained and carried forward to
round 2. In round 2, participants are provided with group feedback and
asked to re-rate the pain features. In round 3, participants are asked to
rate their level of agreement that each pain feature should be included
in a core outcome set.
Results: Phase I: identiﬁcation of pain features
A long-list of 56 pain features was developed from the systematic
review, focus groups and brief interviews with patients. The features
identiﬁed focused on pain intensity, temporal aspects of pain, pain with
activities/movements, pain interference, recovery and pain after TKR,
emotional aspects of pain and use of pain medications.
Phase II: Delphi survey
123 participants have been recruited into the Delphi survey (80 patients
with chronic pain after TKR and 43 clinicians with relevant experience).
In round 1, participants rated the importance of the 56 pain features
identiﬁed in Phase I. Of these 56 pain features, 33 were retained and
carried forward to round 2. Rounds 2 and 3 of the Delphi survey are
currently ongoing and will be completed by January 2014. The core
outcome set will be ﬁnalised by March 2014 and ready for presentation
at the OARSI conference in April 2014.
